Aesther Healthcare Acquisition Corp - Class A
News
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Globe Newswire Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that an equity analyst coverage ...\n more…
Ocean Biomedical rises on positive data from Glioblastoma treatment trial
Seeking Alpha - Healthcare Ocean Biomedical (OCEA) is trading ~5% higher premarket after it published new findings that offer new perspectives on the influence of Chi3L1 in regulating Glioma stem cells. The...\n more…
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Globe Newswire Results published in peer-reviewed Cancer Research share novel insights into Chi3L1s role in modulating Glioma stem cells and reinforces the potential therapeutic impact of Anti-Chi3L1 Providence, RI, April 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA), a biopharma company working to ...\n more…
EXCLUSIVE: Ocean Biomedical Highlights New Results From Anti-Cancer Antibody Validating Tumor Suppression In Animal Models With Brain Tumor
Benzinga Ocean Biomedical Inc's OCEA co-founder, Jack Elias, published new findings in the peer-reviewed journal Cancer Research detailing the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors. What Happened: Results of the research uncovered new data on the efficacy of Ocean Biomedical's anti-Chi3L1 antibody in human glioblastoma implanted mouse models, resulting in a clear reduction in glioblastoma tumor growth.\n more…
Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonatha
Globe Newswire Providence, RI, April 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA),a biopharma company working to accelerate the development of compelling assets from leading research universities and medical centers, announced today that its Scientific Co-founder, Jonathan Kurtis, MD, PhD, ...\n more…
EXCLUSIVE: Ocean Biomedical's Co-Founder Outlines Detailed Data From Malaria Vaccine At Conference
Benzinga Ocean Biomedical Inc's (NASDAQ: OCEA) co-founder, Jonathan Kurtis, presented details of the company's malaria vaccine and treatment approach at the PATH Malaria's annual retreat in Washington, DC.\n more…